Praxis Awarded Patient Recruitment Contract for HCV Research Program
Praxis Awarded Patient Recruitment Contract for HCV Research Program
Brentwood, Tenn., March 3, 2009-Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a major pharmaceutical company for a national study on the Hepatitis C Virus. The study explores an investigational drug’s effectiveness as a mono-treatment as well as an add-on treatment option for the condition affecting almost 4 million Americans.
According to a report issued by the Center for Disease Control, top notable factors and/or behaviors increase the possibility that someone will contract HCV include:
- Low Socioeconomic Status (44%)
- IV Drug Usage (38%)
- Sexual Transmission/Multiple Sex Partners (10%)
- Blood Transfusion Before 1992 (5%)
“There are over 50 trails testing different medical solutions for HCV…over 50. That in conjunction with other difficulty factors shows the immense need for a focused & strategic recruitment effort. We are excited to be partnering on this trial offering customized, executable solutions that will help the sponsor achieve the desired results.” David Fox, Praxis President & CEO adds, “This is also a new partnership for us and we are thrilled to be here and confident in our experience, research and execution strategy put in place that we will see this trail to success.”
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025